Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.

Experts highlight biomarker-driven schizophrenia care—computational subtypes, muscarinic drugs, sharper negative-symptom scoring, and KCC2 targets—reducing trial-and-error prescribing.

Panelists explain why precision tools lag in schizophrenia care and highlight simple biomarkers, faster deals, and clinician-industry collaboration.

Once-monthly subcutaneous olanzapine TEV-749 shows sustained stabilization and remission in schizophrenia, supports direct switching, and avoids post-injection monitoring.

Despite previous failure of PDE10A inhibitor drugs to demonstrate antipsychotic effects in clinical trials, a new "improved" iteration has met phase 2 trial endpoints.

A case report and review of 13 similar cases suggest that late-onset clozapine neutropenia may sometimes reflect neutrophil margination rather than marrow suppression, with corticosteroids, granulocyte colony-stimulating factor, or lithium as possible, carefully monitored paths to continuing treatment.

Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.

Lisa Harding, MD, urges psychiatrists to gather histories, deprescribe safely, and send focused sleep referrals now that orexin agonists have arrived for narcolepsy.